Divergence in patent systems: a discussion of biotechnology transgenic animal patentability and US patent system reform
by Johanna K.P. Dennis
International Journal of Private Law (IJPL), Vol. 1, No. 3/4, 2008

Abstract: While the US patent system has no doubt provided valuable incentives to researchers to innovate, culminating in new discoveries, the same system has restricted the research it seeks to promote. Part 1 of this article addresses the history and present state of the US patent system. In Part 2, biotechnology transgenic animal patentability is discussed, with the 'OncoMouse' technology's impact on major research initiatives as a model for why the US patent system does not work. Part 3 addresses proposed avenues for balancing the various purposes of patents as they relate to biotechnology research and medical inventions.

Online publication date: Thu, 13-Nov-2008

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Private Law (IJPL):
Login with your Inderscience username and password:

    Username:        Password:         

Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com